Japanese Biotech Stock News

Nagase buyback announcement and recent earnings Nagase (TSE:8012) has put a new share repurchase program on the table, alongside reporting nine-month sales of ¥724,069 million and net income of ¥24,976 million for the period to December 31, 2025. See our latest analysis for Nagase. Nagase’s recent buyback announcement and nine month earnings update come after a strong run in the share price, with a 90 day share price return of 24.96% and a 1 year total shareholder return of 63.39%. This...

Revised guidance and earnings set the stage Advantest (TSE:6857) recently raised its full year earnings guidance for the period ending March 31, 2026, and reported sharply higher sales and net income for the nine months to December 31, 2025. See our latest analysis for Advantest. The upgraded guidance and strong nine month earnings have been met with a 21.11% 1 month share price return and a 15.84% year to date share price return, while the 1 year total shareholder return is 186.40%,...

West Japan Railway (TSE:9021) has just combined a Q3 2026 earnings call with nine month results to December 31, 2025, along with fresh guidance for the fiscal year ending March 2026. See our latest analysis for West Japan Railway. The earnings release and new guidance appear to have come at a time when momentum in the shares is already building, with a 30 day share price return of 12.73% and a 1 year total shareholder return of 31.45%. If these results have you looking beyond a single railway...

In early February 2026, Sumitomo Electric Industries raised its full-year guidance, projecting net sales of ¥4.90 trillion and profit attributable to owners of parent of ¥320.00 billion, after reporting nine-month sales of ¥3.69 trillion and net income of ¥177.21 billion through December 31, 2025. The company’s upgraded outlook, alongside higher basic earnings per share guidance of ¥410.30 versus ¥294.90 previously, highlights a marked improvement in profitability expectations within the...

Nippon Shokubai (TSE:4114) just released earnings for the nine months to December 31, 2025, reporting sales of ¥299,332 million and net income of ¥14,372 million, with earnings per share edging higher. See our latest analysis for Nippon Shokubai. The latest nine month update appears to have given the share price fresh momentum, with a 1 day share price return of 4.06% and a 90 day share price return of 35.14%. The 1 year total shareholder return of 36.92% and 5 year total shareholder return...

Why Mitsubishi Motors (TSE:7211) is in focus after its latest earnings Mitsubishi Motors (TSE:7211) is back on investors' radar after reporting a net loss of ¥4,489 million for the nine months to December 31, 2025, reversing from net income a year earlier. Sales for the period were ¥1,976,533 million compared with ¥1,989,291 million previously. Basic loss per share from continuing operations reached ¥3.35 versus basic earnings per share of ¥22.8 a year ago. See our latest analysis for...

Shizuoka Financial Group Inc. has completed its share repurchase program announced on November 7, 2025, buying back 8,406,200 shares for ¥19,999.88 million, including 2,606,200 shares repurchased between January 1 and January 23, 2026. By retiring around 1.55% of its shares through this program, the bank has modestly reduced its share count, which can influence per-share metrics and investor perceptions of capital discipline. We’ll now examine how the completion of this ¥19,999.88 million...

Sanwa Holdings Corporation recently reported results for the nine months ended December 31, 2025, with sales of ¥468,152 million versus ¥475,111 million a year earlier and net income of ¥38,005 million compared with ¥37,291 million. Despite slightly lower sales, the company delivered higher basic earnings per share from continuing operations, pointing to stronger profitability and efficiency. We will now examine how Sanwa Holdings’ improved earnings per share despite weaker sales shapes the...

In early February 2026, Astellas Pharma Inc. raised its fiscal year ending March 31, 2026 guidance, now projecting revenue of ¥2.10 trillion and higher profits on both core and full-year bases, supported by stronger-than-expected earnings per share. The company attributed these upgraded forecasts to robust global demand for its prostate cancer drug XTANDI and overactive bladder franchise, alongside beneficial foreign exchange effects that lifted expected profitability. Next, we’ll examine...

Aisin Corporation reported Q3 FY2026 results on February 3, 2026, with nine-month sales of ¥3,769,158 million and net income of ¥107,375 million, alongside higher basic earnings per share from continuing operations year on year. On the same day, Aisin also unveiled plans to invest about ¥32 billion to expand transmission production in India, signalling a long-term commitment to the country’s growing demand for automatic and continuously variable transmissions. We will now examine how these...

ITOCHU Corporation recently authorized a share repurchase program of up to 13,000,000 shares for ¥20,000 million and reported nine‑month 2025 revenue of ¥10.99 trillion with net income of ¥705.30 billion, both covering the period ended December 31, 2025. Together with new fixed‑rate unsecured bond issuances, these moves underline how ITOCHU is balancing capital returns with funding flexibility while keeping profitability higher than a year earlier despite slightly lower revenue. Against this...

Why JMDC’s latest earnings matter for shareholders JMDC (TSE:4483) has drawn fresh attention after reporting nine month earnings to December 31, 2025, with sales of ¥36,488 million and net income of ¥4,811 million, both higher than the prior year period. See our latest analysis for JMDC. The earnings announcement came as JMDC’s share price moved to ¥3,435, with a 1 day share price return of 4.89%, a 30 day share price return decline of 11.24%, and a 3 year total shareholder return decline of...

On February 3, 2026, JVCKENWOOD Corporation announced a share repurchase program of up to 3,000,000 shares, or 2.08% of issued share capital, for ¥3,000 million, alongside nine‑month results showing sales of ¥258,627 million and net income of ¥12,469 million. The buyback is intended to lift ROE and EPS and help offset supply‑demand effects from recently issued Zero Coupon Convertible Bonds due 2030, signaling management’s focus on capital efficiency. We will now examine how JVCKENWOOD’s new...

As global markets navigate through volatility marked by concerns over artificial intelligence and geopolitical tensions, value-oriented stocks have begun to capture investor attention, particularly in Asia. Identifying undervalued stocks requires a keen eye for companies with strong fundamentals that may be overlooked due to broader market trends or temporary setbacks.

As global markets experience mixed performances, with small-cap and value-oriented stocks gaining traction amid volatility in large-cap technology sectors, investors are increasingly turning their attention to lesser-known opportunities in Asia. In this dynamic environment, identifying stocks that exhibit strong fundamentals and potential for growth can be key to enhancing an investment portfolio.

As global markets navigate a landscape marked by economic shifts and technological disruptions, Asian equities have shown resilience, with Japan's stock indices rising amid domestic optimism and China's manufacturing sector indicating expansion. In this dynamic environment, dividend stocks can offer a measure of stability through regular income streams, making them attractive to investors seeking reliable returns amidst market volatility.

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...

ARIAKE JAPAN (TSE:2815) has updated investors with earnings for the nine months to December 31, 2025, reporting sales of ¥49,931.05 million and net income of ¥6,885.73 million, both above the prior-year period. See our latest analysis for ARIAKE JAPAN. The latest earnings release comes as ARIAKE JAPAN's share price has been firming, with a 7.65% year to date share price return and a 9.07% 90 day share price return. The 3 year total shareholder return of 30.36% contrasts with a 5 year total...

Hirogin Holdings (TSE:7337) drew fresh attention after reporting nine month earnings to 31 December 2025, with higher net interest income, net income, and earnings per share compared with the same period a year earlier. See our latest analysis for Hirogin Holdings. The earnings release appears to have coincided with strong recent momentum, with a 30-day share price return of 14.10% and a 90-day share price return of 30.63%. Over a longer horizon, the 1-year total shareholder return of 65.65%...

Ono Pharmaceutical Co., Ltd. reported past nine‑month results to December 31, 2025, with sales of ¥397,036 million and net income of ¥68,949 million, both higher than the prior year period. The increase in both basic and diluted earnings per share from continuing operations highlights improved profitability over the same nine‑month span a year earlier. Next, we will examine how Ono Pharmaceutical’s higher earnings per share shapes the company’s investment narrative for investors and...

If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...